Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kos Niaspan below-statin pricing planned for pending cholesterol therapy.

Executive Summary

KOS NIASPAN TO CHALLENGE LIPID MARKET WITH BELOW STATIN PRICING: between $1.14 and $1.36 per day at retail, Kos President Daniel Bell declared at a Dillon Read meeting on generic drugs and drug delivery systems in New York April 30. "We believe Niaspan could be extraordinarily attractive to the managed care universe as the preferred starter therapy for patients newly diagnosed who require lipid medication," Bell contended. Merck's Zocor (simvastatin) lists for $1.78 per day at average wholesale prices, according to First DataBank.
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030192

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel